Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale

Core Insights - Lifecore Biomedical has received the remaining $10 million from the sale of its excess high-speed, multi-purpose 10-head isolator filler, completing a $17 million transaction ahead of schedule [1][2] - The company emphasizes its disciplined capital management approach and the positive momentum from recent operational enhancements, including the installation of a high-speed 5-head filler with a capacity of up to $300 million in annual revenue [2] Financial Developments - The total proceeds from the sale of the 10-head isolator filler amounted to $17 million, with $7 million received at the close of the transaction in early 2025 [1][2] - The accelerated payment from the buyer was made as a lump sum rather than the originally planned 18-month installment plan [1] Company Overview - Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products [3] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and serves global and emerging biopharmaceutical and biotechnology companies [3]